

Robert Halmosi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5729436/publications.pdf>

Version: 2024-02-01

43
papers

2,297
citations

304368

22
h-index

253896

43
g-index

45
all docs

45
docs citations

45
times ranked

3442
citing authors

#	ARTICLE	IF	CITATIONS
1	The Genetic Architecture of Hypertrophic Cardiomyopathy in Hungary: Analysis of 242 Patients with a Panel of 98 Genes. <i>Diagnostics</i> , 2022, 12, 1132.	1.3	4
2	BGP-15 Protects against Heart Failure by Enhanced Mitochondrial Biogenesis and Decreased Fibrotic Remodelling in Spontaneously Hypertensive Rats. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-13.	1.9	12
3	Modulation of Mitochondrial Quality Control Processes by BGP-15 in Oxidative Stress Scenarios: From Cell Culture to Heart Failure. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-22.	1.9	3
4	Protective effects of the novel amine-oxidase inhibitor multi-target drug SZV 1287 on streptozotocin-induced beta cell damage and diabetic complications in rats. <i>Biomedicine and Pharmacotherapy</i> , 2021, 134, 111105.	2.5	9
5	Mitochondrial protective effects of PARP-inhibition in hypertension-induced myocardial remodeling and in stressed cardiomyocytes. <i>Life Sciences</i> , 2021, 268, 118936.	2.0	17
6	L-arginine, asymmetric and symmetric dimethylarginine for early outcome prediction in unselected cardiac arrest victims: a prospective cohort study. <i>Internal and Emergency Medicine</i> , 2021, , 1.	1.0	1
7	The Effect of Resveratrol on the Cardiovascular System from Molecular Mechanisms to Clinical Results. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10152.	1.8	35
8	Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 1999-2007.	2.9	22
9	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 92-102.	2.9	81
10	Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-8.	1.1	14
11	Resveratrol Improves Heart Function by Moderating Inflammatory Processes in Patients with Systolic Heart Failure. <i>Antioxidants</i> , 2020, 9, 1108.	2.2	20
12	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1378-1389.	2.9	83
13	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	2.9	36
14	The Effects of Bradykinin B1 Receptor Antagonism on the Myocardial and Vascular Consequences of Hypertension in SHR Rats. <i>Frontiers in Physiology</i> , 2019, 10, 624.	1.3	6
15	Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	2.9	35
16	Acute heart failure congestion and perfusion status: Impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	2.9	170
17	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. <i>JACC: Heart Failure</i> , 2018, 6, 452-462.	1.9	94
18	Interactions between iodinated contrast media and tissue plasminogen activator: In vitro comparison study. <i>Clinical Hemorheology and Microcirculation</i> , 2017, 66, 167-174.	0.9	1

#	ARTICLE	IF	CITATIONS
19	Integrative characterization of chronic cigarette smoke-induced cardiopulmonary comorbidities in a mouse model. <i>Environmental Pollution</i> , 2017, 229, 746-759.	3.7	13
20	Cardioprotective Effect of Resveratrol in a Postinfarction Heart Failure Model. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-10.	1.9	86
21	Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats. <i>PLoS ONE</i> , 2017, 12, e0174401.	1.1	12
22	Doxycycline protects against ROS-induced mitochondrial fragmentation and ISO-induced heart failure. <i>PLoS ONE</i> , 2017, 12, e0175195.	1.1	42
23	PARP inhibition and postinfarction myocardial remodeling. <i>International Journal of Cardiology</i> , 2016, 217, S52-S59.	0.8	14
24	A quinazoline-derivative compound with PARP inhibitory effect suppresses hypertension-induced vascular alterations in spontaneously hypertensive rats. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 935-944.	1.8	23
25	PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3 β and Several PKC Isoforms. <i>PLoS ONE</i> , 2014, 9, e102148.	1.1	29
26	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-term Registry. <i>European Journal of Heart Failure</i> , 2013, 15, 1173-1184.	2.9	533
27	Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. <i>Clinical Hemorheology and Microcirculation</i> , 2012, 50, 179-187.	0.9	288
28	Regulation of Kinase Cascade Activation and Heat Shock Protein Expression by Poly(ADP-ribose) Polymerase Inhibition in Doxorubicin-induced Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 58, 380-391.	0.8	23
29	Enhancement of Organ Regeneration in Animal Models by a Stem Cell-Stimulating Plant Mixture. <i>Journal of Medicinal Food</i> , 2010, 13, 599-604.	0.8	1
30	PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. <i>Cardiovascular Research</i> , 2009, 83, 501-510.	1.8	61
31	Effect of L-2286, a Poly(ADP-ribose)polymerase Inhibitor and Enalapril on Myocardial Remodeling and Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 52, 253-261.	0.8	23
32	PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3 β pathway. <i>Journal of Molecular and Cellular Cardiology</i> , 2006, 41, 149-159.	0.9	52
33	The Role of Akt and Mitogen-Activated Protein Kinase Systems in the Protective Effect of Poly(ADP-Ribose) Polymerase Inhibition in Langendorff Perfused and in Isoproterenol-Damaged Rat Hearts. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 273-282.	1.3	44
34	Prevention of Doxorubicin-Induced Acute Cardiotoxicity by an Experimental Antioxidant Compound. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 45, 36-43.	0.8	55
35	Drug-induced myocardial infarction in young patients. <i>International Journal of Cardiology</i> , 2005, 98, 169-170.	0.8	11
36	Akt activation induced by an antioxidant compound during ischemia-reperfusion. <i>Free Radical Biology and Medicine</i> , 2003, 35, 1051-1063.	1.3	41

#	ARTICLE	IF	CITATIONS
37	Impact of a novel cardioprotective agent on the ischaemia-reperfusion-induced Akt kinase activation. <i>Biochemical Pharmacology</i> , 2003, 66, 2263-2272.	2.0	18
38	2,2,5,5-Tetramethylpyrroline-Based Compounds in Prevention of Oxyradical-induced Myocardial Damage. <i>Journal of Cardiovascular Pharmacology</i> , 2002, 40, 854-867.	0.8	15
39	In Vitro Antioxidant Properties of Pentoxifylline, Piracetam, and Vinpocetine. <i>Clinical Neuropharmacology</i> , 2002, 25, 37-42.	0.2	78
40	The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals. <i>Cardiovascular Research</i> , 2001, 52, 153-160.	1.8	18
41	Effect of Poly(ADP-Ribose) Polymerase Inhibitors on the Ischemia-Reperfusion-Induced Oxidative Cell Damage and Mitochondrial Metabolism in Langendorff Heart Perfusion System. <i>Molecular Pharmacology</i> , 2001, 59, 1497-1505.	1.0	136
42	QRS Score: A Composite Index of Exercise-Induced Changes in the Q, R, and S Waves During Exercise Stress Testing in Patients with Ischemic Heart Disease. <i>Annals of Noninvasive Electrocardiology</i> , 2001, 6, 310-318.	0.5	10
43	Scavenger Effect of Experimental and Clinically Used Cardiovascular Drugs. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, 745-753.	0.8	23